FDA Webview Site FDA Review Site FDA Updater Site
header.gif
Username:
Password:
 

human drugs
animal drugs
biologics
eirs 483s
medical devices
marketing
email
search our site
  
FDA-RELATED NEWS
 
 
 
TXT Trump Lashes Out at Merck CEO After Charlottesville
08/14/2017
 
 
TXT FDA Alert on Obesity Balloon Devices After 5 Deaths
08/10/2017
 
 
TXT Trump Declares Opioid Crisis a ‘National Emergency’
08/11/2017
 
 
TXT FDA Sued Over Orenitram Orphan Drug Denial
08/10/2017
 
 
TXT FDA Cautions Doctor Over ‘3-Parent Baby’
08/08/2017
 
 
TXT OGD Seeing Record Year with ANDA Approvals
08/09/2017
 
 
TXT New DTC Research Examines New Risk Presentation Model
08/07/2017
 
 
TXT Sunshine Needed on Doc Drug Company Payments: Grassley
08/10/2017
 
 
TXT FDA HQ Environmental Impact Statement
08/10/2017
 
 
TXT FDA Issues Medical Device Development Tool Guidance
08/09/2017
 
 
TXT Product Approval Summaries
08/13/2017
 
 
TXT Since Our Last Issue ...
08/13/2017
 
 
TXT Latest Federal Register Notices
08/13/2017
 
 
TXT Court Denies Amgen Epogen Biosimilar Patent Appeal
08/10/2017
 
 
TXT FDA Sued Over Absent Petition Response
08/10/2017
 
 
TXT Medical Device Pre-Cert FAQs
08/10/2017
 
 
TXT FDA Grants, Denies Prandin/Plavix Petition
08/09/2017
 
 
TXT China Joins ICH Drug Harmonization
08/09/2017
 
 
TXT Allergan Asks for Restasis ANDA Restrictions
08/09/2017
 
 
TXT Draft Guide on Biologic CMC Post-Approval Changes
08/08/2017
 
 
TXT Comments Sought on ICH Safety Reporting Waivers
08/08/2017
 
 
TXT NCI Study Finds Cancer Immunotherapy Genes
08/08/2017
 
 
TXT Pew Launching Antibiotic Info-Sharing Platform
08/08/2017
 
 
TXT Latest FDA Warning Letters
08/08/2017
 
 
TXT CGMP Consultant Recommended for Cellex-C
08/08/2017
 
 
TXT Multiple Violations Found at Philippines’ Skin Sciences
08/08/2017
 
 
TXT 10 Inspection Observations in Biocon ’483
08/08/2017
 
 
TXT Meeting Next Month on Assessing Benefits/Risks
08/08/2017
 
 
TXT Nature Editorial Urges Academic Scientists to Help FDA
08/07/2017
 
 
 
 
The most authoritative FDA news analysis each week is found in the pages of Dickinson's FDA Review. Since 1984, this newsletter has been providing in-depth reports on the most significant FDA developments affecting the pharmaceutical, medical device, biologics and veterinary medicines industries. Unlike other media, FDA Review eliminates time-wasting minutia and presents in clear, concise language the essence of what's really important - and why. It is the publication that FDA officials themselves read. Delivered in the middle of each week, FDA Review presents:
  • The latest agency policy developments, often before they're officially announced;
  • Major news insights, follow-ups and reactions in each product area;
  • Summaries of the latest Warning Letters;
  • The newest product approvals;
  • Summaries of the latest FDA Federal Register notices;
  • Summaries of DDMAC letters;
  • Related industry news capsules;
  • The industry's most concise FDA news index;
  • Inside-FDA news briefs
You can rely on FDA Review to provide only what's important - in the most convenient and time-saving